82 related articles for article (PubMed ID: 1931452)
1. Anthracyclines.
Myers C
Cancer Chemother Biol Response Modif; 1991; 12():43-9. PubMed ID: 1931452
[No Abstract] [Full Text] [Related]
2. [New anthracyclines in the treatment of solid tumors in the advanced stage].
Pannuti F; Martoni A; Lelli G; Camaggi CM; Strocchi E; Fruet F
G Ital Chemioter; 1985; 32(1):49-56. PubMed ID: 3868636
[No Abstract] [Full Text] [Related]
3. [Enhancing factors in the cardiotoxicity of anthracyclines].
Sanz Manrique N; Valcarce Pérez J; Broto Escapa P; Escribano Subías J; Casaldáliga Ferrer J; Moraga Llop FA; Sánchez de Toledo Codina J
An Esp Pediatr; 1990 Jan; 32(1):11-4. PubMed ID: 2327660
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F
Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836
[TBL] [Abstract][Full Text] [Related]
5. [4'-epidoxorubicin].
Mechl Z
Cas Lek Cesk; 1985 Jun; 124(24):755-7. PubMed ID: 3860300
[No Abstract] [Full Text] [Related]
6. Anthracyclines.
Batist G
Cancer Chemother Biol Response Modif; 2001; 19():47-58. PubMed ID: 11686029
[No Abstract] [Full Text] [Related]
7. Adriamycin, an antitumour antibiotic: a review with special reference to daunomycin.
Skovsgaard T; Nissen NI
Dan Med Bull; 1975 Feb; 22(2):62-73. PubMed ID: 1093818
[No Abstract] [Full Text] [Related]
8. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
9. [Recent data on anthracyclines].
Marty M; Espie M; Gisselbrecht C; Lagier G
Pathol Biol (Paris); 1987 Jan; 35(1):5-10. PubMed ID: 3550613
[No Abstract] [Full Text] [Related]
10. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
11. Review: doxorubicin delivery systems based on chitosan for cancer therapy.
Tan ML; Choong PF; Dass CR
J Pharm Pharmacol; 2009 Feb; 61(2):131-42. PubMed ID: 19178759
[TBL] [Abstract][Full Text] [Related]
12. [New anthracyclines].
Ogawa M; Ariyoshi Y
Gan To Kagaku Ryoho; 1993 Jan; 20(1):27-33. PubMed ID: 8422185
[TBL] [Abstract][Full Text] [Related]
13. Low-dose anthracyclines may block HIF-1 and stop tumor growth.
Hede K
J Natl Cancer Inst; 2009 Mar; 101(6):368-70. PubMed ID: 19276456
[No Abstract] [Full Text] [Related]
14. Ongoing phase I and II studies of novel anthracyclines.
Sessa C; Valota O; Geroni C
Cardiovasc Toxicol; 2007; 7(2):75-9. PubMed ID: 17652808
[TBL] [Abstract][Full Text] [Related]
15. [The effectiveness of adjuvant chemotherapy with anthracyclines (adriablastin, doxorubicin) for stage-IIb-IIIa breast cancer].
Semiglazov BF; Bozhok AA; Ivanova OA; Ivanov VG; Barash NIu; Orlov AA; Golubeva OM; Seleznev IK; Migmanova NSh; Popova RT
Vopr Onkol; 1998; 44(4):403-7. PubMed ID: 9807202
[TBL] [Abstract][Full Text] [Related]
16. [The treatment of cancer by anthracyclines].
Brenner J; Brenner HJ
Harefuah; 1983 Mar; 104(5):205-7. PubMed ID: 6582021
[No Abstract] [Full Text] [Related]
17. Recovery from anthracycline cardiomyopathy--how can it be explained?
Christiansen S
J Heart Lung Transplant; 2009 Jul; 28(7):751. PubMed ID: 19560709
[No Abstract] [Full Text] [Related]
18. Doxorubicin in experimental and clinical heart failure.
Christiansen S; Autschbach R
Eur J Cardiothorac Surg; 2006 Oct; 30(4):611-6. PubMed ID: 16901709
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator.
Rudzinski T; Ciesielczyk M; Religa W; Bednarkiewicz Z; Krzeminska-Pakula M
Europace; 2007 May; 9(5):278-80. PubMed ID: 17383986
[TBL] [Abstract][Full Text] [Related]
20. Fever-range whole body hyperthermia increases the number of perfused tumor blood vessels and therapeutic efficacy of liposomally encapsulated doxorubicin.
Xu Y; Choi J; Hylander B; Sen A; Evans SS; Kraybill WG; Repasky EA
Int J Hyperthermia; 2007 Sep; 23(6):513-27. PubMed ID: 17952765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
